Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, USA.
Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA.
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.01715-20.
Vancomycin-resistant enterococci (VRE) represent a major public health threat that requires the development of new therapeutics. In the present study, acetazolamide (AZM) was evaluated against enterococci. It inhibited different enterococcal strains tested at clinically achievable concentrations. Moreover, AZM outperformed linezolid, the drug of choice for VRE infections, in two VRE mouse models-murine colonization-reduction and VRE septicemia. Collectively, these results indicate that AZM warrants consideration as a promising treatment option for VRE infections.
耐万古霉素肠球菌（VRE）是一个主要的公共卫生威胁，需要开发新的治疗方法。在本研究中，乙酰唑胺（AZM）被评估用于肠球菌。它在临床可达到的浓度下抑制了不同的肠球菌菌株。此外，AZM 在两种 VRE 小鼠模型——鼠定植减少和 VRE 败血症中优于万古霉素，万古霉素是 VRE 感染的首选药物。总的来说，这些结果表明 AZM 值得考虑作为 VRE 感染的一种有前途的治疗选择。
